Main Menu

Dicerna Pharmaceuticals, Inc.

(NASDAQ GS: DRNA)

Rigrodsky Law, P.A. is investigating Dicerna Pharmaceuticals, Inc. (“Dicerna”) regarding possible breaches of fiduciary duties and other violations of law related to Dicerna’s agreement to be acquired by Novo Nordisk A/S. Under the terms of the agreement, Dicerna’s shareholders will receive $38.25 in cash for each share of Dicerna common stock they own.

Join This Action

Alternatively, you may upload your transactions using the upload button below or email them to info@rl-legal.com.

Draw your signature below using your mouse* [Clear]

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

Date of signing: 12/03/2021


* Indicates a required field.

Back to Page